Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify Company / Ticker to Get the Summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Sellas Life Sciences Group Inc
SLSCurrent price
1.31 USD
+0.04 USD (+3.15%)
Last closed
1.04 USD
Company
www.sellaslifesciences.com
ISIN
US81642T2096
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Capitalization
119 009 176 USD
Yield for 12 month
-14.94 %
1Y
3Y
5Y
10Y
15Y
SLS
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York. Address: 7 Times Square, New York, NY, United States, 10036
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
5.83 USDP/E ratio
–Dividend Yield
–Current Year
–
Last Year
–
Current Quarter
–
Last Quarter
–
Current Year
–
Last Year
–
Current Quarter
–
Last Quarter
–
Key Figures SLS
1 year
3 years
5 years
10 years
EBITDA
–
Operating Margin TTM
Price to Earnings
–
Return On Assets TTM
-153.57 %
PEG Ratio
–
Return On Equity TTM
-4 147.88 %
Wall Street Target Price
5.83 USD
Revenue TTM
–
Book Value
0.13 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
-82.50 %
Dividend Yield
–
Gross Profit TTM
900 000 USD
Earnings per share
-0.50 USD
Diluted Eps TTM
-0.50 USD
Most Recent Quarter
IV 2024
Quarterly Earnings Growth YOY
–
Profit Margin
–
Dividend Analytics SLS
Max Ratio
>10 - expected double digit dividend yield on cost over 10Y >5 - expected 5-9 dividend yield on cost over 10Y <5 - expected <5 dividend yield on cost over 10Y MaxRatio is an estimated 10Y dividend yield on cost calculated by combining the current dividend yield with the 5-year & 10-year average dividend growth rate, projected over the next 10 years discounted based on current Financial Score. It provides a projected outlook on future dividend returns.
–5Y Dividend Growth
–Consecutive Years
–5Y Average Payout Ratio
–Dividend History SLS
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Ex Dividend Date
–
Dividend CAGR 3Y
–
Dividend CAGR 5Y
–
Dividend CAGR 10Y
–
Consecutive Years
Consistent Years
Continuous Dividends
Forward Annual Dividend Yield
–
Forward Annual Dividend
– USD
Last Split Factor
1:50
Payout Ratio
–
Last Split Date
08.11.2019
Stock Valuation SLS
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
–
Enterprise Value Revenue
20.84
Price Sales TTM
26.90
Enterprise Value EBITDA
-1.71
Price Book MRQ
12.57
Financials SLS
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators SLS
For 52 weeks
0.77 USD
1.84 USD
50 Day MA
1.19 USD
Shares Short Prior Month
7 845 644
200 Day MA
1.18 USD
Short Ratio
9.17
Shares Short
8 176 648
Short Percent
9.01 %
BeatStart